Recombinant p. vivax merozoite protein-1 p42 vaccine
CA 2443947 C · Owner: Walter Reed Army Institute Of Research · Inventors: Dutta, Sheetij; Ware, Lisa A.; Lanar, David E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
In this application is the expression and purification of a recombinant Plasmodium vivax (SalI) PvMSP-1 p42. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant PvMSP-1 p42 is useful as a diagnostic reagent, for use in antibody production and as a vaccine.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 18, 2002 and granted January 31, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 18, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 18, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.